Vemurafenib and radiation therapy in melanoma brain metastases

Journal of Neuro-Oncology

Volumn 113, Issue 3, 2013, Pages 411-416

  Narayana, Ashwatha ^a   Mathew, Maya ^a   Tam, Moses ^a   Kannan, Rajni ^a   Madden, Kathleen M ^a   Golfinos, John G ^a   Parker, Erik C ^a   Ott, Patrick A ^a   Pavlick, Anna C ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BRAF; Brain metastases; Melanoma; Vemurafenib

Indexed keywords

IPILIMUMAB; STEROID; TEMOZOLOMIDE; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHEMA; FATIGUE; GENE MUTATION; HUMAN; LIVER TOXICITY; MELANOMA; MORBIDITY; MOUTH PAIN; OVERALL SURVIVAL; PILOT STUDY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION NECROSIS; RADIATION RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; FEMALE; FOLLOW UP; GENETICS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RADIOSURGERY; SECONDARY; SKULL IRRADIATION; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RADIOSURGERY; RETROSPECTIVE STUDIES; SULFONAMIDES; SURVIVAL RATE;

EID: 84879422839     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1127-1     Document Type: Article

References (24)

1. Staudt M et al (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102(8):1213-1218
2. Fife KM et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7):1293-1300
3. Selek U et al (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 59(4):1097-1106
4. Soffietti R, Ruda R, Trevisan E (2008) Brain metastases: current management and new developments. Curr Opin Oncol 20(6):676-684
5. Gonzalez-martinez J et al (2002) Gamma knife radiosurgery for intracranial metastatic melanoma: a 6-year experience. J Neurosurg 97(supplement 5):494-498
6. Hwu W-J et al (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma. Cancer 103(12):2590-2597
7. Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954
8. Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135-2147
9. Long GV et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087-1095
10. Falchook GS et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893-1901
11. Bollag G et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315):596-599
12. Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516
13. Sosman JA et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707-714
14. Rochet NM et al (2012) Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 87(10):976-981
15. Soffietti R, Trevisan E, Ruda R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6):679-686
16. Mittapalli RK et al (2012) Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342(1):33-40
17. Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306-2312
18. Agarwala SS et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22(11):2101-2107
19. Atkins MB et al (2008) Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113(8):2139-2145
20. Hwu WJ et al (2005) Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103(12):2590-2597
21. Avril MF et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22(6):1118-1125
22. Margolin K et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459-465
23. Rochet NM, Kottschade LA, Markovic SN (2011) Vemurafenib for melanoma metastases to the brain. N Engl J Med 365(25):2439-2441
24. Sambade MJ et al (2011) Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 98(3):394-399